Camille L. Bedrosian
Keck Hospital of USC(US)
Publications by Year
Research Areas
Complement system in diseases, Renal Diseases and Glomerulopathies, PI3K/AKT/mTOR signaling in cancer, Adenosine and Purinergic Signaling, Iron Metabolism and Disorders
Most-Cited Works
- → Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome(2013)1,539 cited
- → C3 glomerulopathy: consensus report(2013)627 cited
- → Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies(2015)412 cited
- → Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial(2016)301 cited
- → Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome(2016)290 cited
- → Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies(2008)271 cited
- → Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry(2014)262 cited
- → Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis(2019)231 cited
- → A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies(2008)225 cited
- → Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS(2015)195 cited